The popular artificial sweetener sucralose may impair cancer immunotherapy by depleting arginine—an amino acid essential for ...

A global study demonstrated that CAR-T cell therapy is linked to significantly increased risks of secondary cancers—8.9-fold ...

Eli Lilly’s first-in-class non-covalent BTK inhibitor, demonstrated superior overall response rates compared to Imbruvica in ...

Gnosis has announced the launch of EdenDx, the first non-invasive, liquid-based cytology test for early endometrial cancer ...

Researchers have enhanced cisplatin’s efficacy in advanced NSCLC by transplanting functional mitochondria from cardiomyocytes ...

Nuvisertib, an oral PIM1 kinase inhibitor from Sumitomo Pharma, has received Orphan Drug Designation from the EMA for ...

Antibody-drug conjugates and bispecific antibodies are reshaping the future of targeted therapy in oncology and immunology.

The FDA granted Priority Review and Breakthrough Therapy Designation to Imfinzi for resectable gastric and GEJ cancers, based ...

A new study published in Cancer Cell reveals that blocking a key nutrient-scavenging process in pancreatic tumors reprograms the tumor microenvironment—reducing fibrosis, enhancing T cell infiltration ...

In this exclusive interview, Dr. Raza Bokhari, CEO of Medicus Pharma, introduces SkinJect patch—a cellulose-based microneedle ...

Macrophage checkpoint inhibitors promise a transformative role in cancer immunotherapy; by targeting the “don’t eat me” ...

A team of international scientists has uncovered a novel way to boost the cancer-killing power of the immune system’s T cells—by flipping a metabolic switch deep within their mitochondria.